Study explores the interaction between SARS-CoV-2’s non-structural protein 3 (NSP3) and proteins related to Fragile X mental retardation (FMRPs), shedding light on COVID-19 pathophysiology. The research suggests that the virus exploits these host cell proteins for effective infection and possibly interferes with antiviral defense mechanisms, offering new insights into the genetic basis of Fragile X syndrome.
Amylyx to voluntarily withdraw ALS drug Relyvrio after Phase 3 fail, will lay off around 70%
Amylyx announced Thursday morning that it will pull its ALS drug Relyvrio from the US and Canadian markets. The decision comes as Amylyx will also
April 5, 2024